Hypermarcas (OTCMKTS:HYPMY) Releases Earnings Results, Beats Estimates By $0.01 EPS

Hypermarcas (OTCMKTS:HYPMY) announced its quarterly earnings data on Thursday. The company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.13 by $0.01, Zacks reports. Hypermarcas had a return on equity of 14.08% and a net margin of 19.41%.

Hypermarcas Stock Down 0.8%

Shares of HYPMY stock traded down $0.03 on Thursday, hitting $4.13. The company had a trading volume of 3,851 shares, compared to its average volume of 22,289. Hypermarcas has a twelve month low of $3.71 and a twelve month high of $5.50. The firm has a market cap of $2.91 billion, a P/E ratio of 8.60 and a beta of 0.70. The company has a 50-day moving average price of $4.10 and a 200-day moving average price of $4.37.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Jefferies Financial Group raised shares of Hypermarcas to a “strong-buy” rating in a research report on Monday, July 20th. Zacks Research raised shares of Hypermarcas to a “hold” rating in a research report on Wednesday, April 29th. One equities research analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy”.

Hypermarcas Company Profile

Hypermarcas SA is a Brazil-based consumer health and pharmaceutical company whose shares trade over the counter in the United States under the symbol HYPMY. Founded in the early 2000s and headquartered in Rio de Janeiro, the company operates as a holding group for a broad portfolio of branded products in the healthcare and personal care sectors.

Through its various subsidiaries, Hypermarcas develops, manufactures and markets prescription and over-the-counter medications, alongside personal care, baby care, home care and nutritional supplement products.